Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inozyme Pharma (INZY) has issued an announcement.
Inozyme Pharma, Inc. released promising preliminary results from Phase 1/2 clinical trials of INZ-701 for ABCC6 and ENPP1 Deficiencies, showing potential benefits in cardiovascular and retinal health, as well as improved patient-reported outcomes. The drug was well-tolerated with a favorable safety and immunogenicity profile across both patient groups. These findings support the drug’s potential for disease modification, prompting the company to pursue regulatory discussions for a pivotal trial aimed at treating pediatric ABCC6 Deficiency, which is associated with severe early-onset cardiovascular disease.
For a thorough assessment of INZY stock, go to TipRanks’ Stock Analysis page.